Antigencs Inc., of New York, said follow-up data from its Phase III trial of therapeutic cancer vaccine Oncophage (vitespen) showed that, in a substantial subset of patients at intermediate risk for disease recurrence, the product demonstrated a clinically significant improvement in recurrence-free survival of about 45 percent
According to SWOG, the 198 patients enrolled in the trial, prior to the closure, are sufficient to provide data analysis and evaluate the primary endpoint of progression-free survival (PFS) in the two arms of the trial
In addition, the mean progression-free survival was 96 days for Vectibix-treated patients compared to 60 days...Its primary efficacy endpoint is overall survival, and overall response rates, progression-free survival and disease control also will be evaluated. (See BioWorld Today, Jan. 4, 2007
Data examined to date showed that patients on HyCAMP were able to receive more doses (a median of six cycles of therapy compared to two for irinotecan along), and median progression-free survival for HyCAMP patients was 5.2 months, compared to 2.4 months for the Irinotecan arm
The primary endpoint is progression-free survival from randomization until disease progression or death...The primary endpoint is progression-free survival rate after 16 weeks
The first designation is in the first-line treatment of metastatic colorectal cancer to improve progression-free survival and overall survival when added to Avastin-containing 5-fluorourocil (5-FU)-based chemotherapy regimens
reported that one of two outcome studies of Prostascint indicated that individualizing seed implantation in prostate cancer regimens resulted in high rates of biochemical disease-free survival (bDFS
and Spectrum Pharmaceuticals Inc., of Irvine, Calif., reported the final progression-free survival results from the Phase III SPARC registration trial of satraplatin, a platinum-based agent
Secondary endpoints will evaluate the duration of response, progression-free survival, overall survival, time to response and various safety and pharmacokinetic parameters
Forty-five patients may receive up to six 21-day cycles at various sites in the U.S. In addition to safety, the trial is investigating the efficacy of glufosfamide as determined by response rate, duration of response and progression-free survival based on changes in the serum tumor marker level CA-125, tumor assessments and overall survival
Onyx Pharmaceuticals Inc., of Emeryville, Calif., and Bayer Pharmaceuticals Corp., of West Haven, Conn., said results of a pivotal Phase III trial demonstrate that Nexavar (sorafenib) tablets doubled median progression-free survival in patients with advanced renal-cell carcinoma...Clinic Roundup
Secondary objectives include assessing progression-free survival, overall survival, and duration of response and to continue characterizing the pharmacokinetic and pharmacodynamic profiles of XL880
Point Therapeutics Inc., of Boston, said finalized data from its 55-patient Phase II study of talabostat in combination with docetaxel in Stage IIIb/IV non-small-cell lung cancer showed an overall median progression-free survival of four months and an overall median survival of 7.8 months
Antigencs Inc., of New York, said follow-up data from its Phase III trial of therapeutic cancer vaccine Oncophage (vitespen) showed that, in a substantial subset of patients at intermediate risk for disease recurrence, the product demonstrated a clinically significant improvement in recurrence-free survival of about 45 percent